Fourth quarter 2024 CAPLYTA net product sales grew to $199.2 million, representing a 51% increase over the same period in…
Extends cash runway well into mid-2026; no new/replacement warrants issuedKENMORE, N.Y., Feb. 21, 2025 (GLOBE NEWSWIRE) -- Firefly Neuroscience, Inc.…
WEST VALLEY CITY, Utah, Feb. 21, 2025 (GLOBE NEWSWIRE) -- Nusano, a physics company committed to bringing supply stability and…
In October 2024, the U.S. Food and Drug Administration (FDA) approved SELARSDI™ for all indications matching the reference product Stelara®…
In October 2024, the U.S. Food and Drug Administration (FDA) approved SELARSDI™ for all indications matching the reference product Stelara®…
In October 2024, the U.S. Food and Drug Administration (FDA) approved SELARSDI™ for all indications matching the reference product Stelara®…
Put Option Agreements signed to date with 2025 OCEANEs holders representing 95.3% of the outstanding 2025 OCEANEs2025 OCEANEs holders' general…
Abivax to Host Key Opinion Leader (KOL) Webcast on March 17, 2025 Event to Feature Renowned Gastroenterologist Dr. David Rubin,…
LOS ANGELES, Feb. 20, 2025 (GLOBE NEWSWIRE) -- ACELYRIN, INC. (Nasdaq: SLRN), a late-stage clinical biopharma company focused on accelerating…
Phoenix Molecular Designs Infographic Introduction to PhoenixMD PMD-026 is a first-in-class and best-in-class pan-RSK inhibitorFavorable mPFS demonstrated in Phase 1/1b…